Skip to main content
ALEMBIC PHARMACEUTICALS LIMITED logo

ALEMBIC PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · APLLTD ISIN · INE901L01018 LEI · 335800PM173KNG818V30 BSE.NS Manufacturing
Open in API
Filings indexed 1,365 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country IN India
Listing BSE.NS APLLTD

About ALEMBIC PHARMACEUTICALS LIMITED

https://www.alembicpharmaceuticals.com

Alembic Pharmaceuticals Limited is a vertically integrated pharmaceutical organization engaged in the development, manufacturing, and marketing of generic pharmaceutical products, active pharmaceutical ingredients (APIs), and formulations. Established in 1907, the company operates advanced research and development centers and manufacturing facilities that adhere to international regulatory standards, including USFDA compliance. Its diverse product portfolio covers key therapeutic areas such as anti-infectives, cardiology, gynecology, gastrointestinal, and dermatology. Alembic maintains a strong global presence, supplying high-quality medications to markets in North America, Europe, and various emerging regions. The company prioritizes innovation through its focus on complex generics and specialty products, aiming to provide affordable and effective healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 75% confidence The document is a stock exchange filing by Alembic Pharmaceuticals Limited notifying the exchanges (BSE and NSE) of a regulatory event: USFDA final approval for a product. It is a press release style corporate announcement, not a financial report, not an annual or interim report, not a management or investor presentation, and not a prospectus or proxy. It falls under general regulatory announcements. Therefore, it best fits the Regulatory Filings category (RNS).
2026-05-22 English
Alembic Pharmaceuticals Limited receives USFDA Final Approval for Levothyroxine Sodium Tablets USP.
Regulatory Filings Classification · 85% confidence The document is a press release filed with stock exchanges announcing USFDA final approval of a pharmaceutical product. It does not present financial statements, voting results, management changes, or capital transactions. It is a standard regulatory announcement to exchanges and falls into the fallback category for miscellaneous regulatory filings.
2026-05-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is titled “Transcript of Post Results Conference Call held on 15th May, 2026” and contains the full Q4 FY ’26 earnings conference call transcript, including management presentations and a Q&A session. This matches the definition of a Call Transcript (CT) filing.
2026-05-21 English
Please find attached.
Call Transcript Classification · 95% confidence The document is the full text transcript of Alembic Pharmaceuticals’ Q4 FY ’26 post-results earnings conference call held on May 15, 2026, including moderator and speaker Q&A. This matches the definition of a Call Transcript (CT).
2026-05-21 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings Classification · 85% confidence The document is a mandatory declaration under Regulation 31(4) of SEBI’s Substantial Acquisition and Takeover Regulations, stating that no encumbrances were created on the promoters’ shareholding during the financial year. It is a compliance/regulatory announcement rather than a financial report, results announcement, share transaction or threshold‐crossing disclosure. Therefore it falls under the general “Regulatory Filings” category (RNS).
2026-05-18 English
Newspaper Publication of Audited Financial Results as on 31st March, 2026.
Earnings Release Classification · 87% confidence The document is a formal intimation under SEBI Listing Regulations that includes the extract of consolidated audited financial results for the quarter and financial year ended 31 March 2026. It provides key highlights (total income, net profit, EPS, etc.) in a newspaper-cutting format, analogous to an initial earnings announcement. It does not constitute a full annual report or interim report with full statements, nor is it merely a notification of report availability. It is a periodical results disclosure, matching the definition of an Earnings Release. FY 2026
2026-05-16 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.